Skip to main content
Log in

Quantitative Prognostic Prediction Using ADV Score for Hepatocellular Carcinoma Following Living Donor Liver Transplantation

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery

Abstract

Background

We assessed the prognostic impact of the ADV score (α-fetoprotein [AFP]–des-γ-carboxyprothrombin [DCP]–tumor volume [TV] score) for predicting hepatocellular carcinoma (HCC) recurrence and patient survival after living donor liver transplantation (LDLT).

Methods

This study included 843 HCC patients who underwent LDLT between January 2006 and December 2015 at Asan Medical Center. These cases were divided into treatment-naïve (TN, n = 256]) and pretransplant-treated (PT, n = 587 [69.6%]) groups.

Results

There were weak or nearly no correlations among AFP, DCP, and TV. There existed high correlations between the pretransplant and explant findings regarding tumor number, size, and ADV score. Right lobe grafts were implanted in 760 (90.2%) patients. HCC recurrence and all-cause patient death occurred in 182 (15.9%) and 126 (15.0%) respectively during the follow-up period for 75.6 ± 35.5 months. The 5-year tumor recurrence (TR) and overall patient survival (OS) rates were 21.5% and 86.2%, respectively. The PT group showed higher TR (p < 0.001) and lower OS rates (p < 0.001). TR and OS were closely correlated with both pretransplant and explant ADV scores in the TN and PT groups. The ADV score enabled further prognostic stratification of the patients within and beyond the Milan, UCSF, and Asan Medical Center criteria. Compared with the 7 pre-existing selection criteria, ADV score with a cutoff of 5log showed the highest prognostic contrast regarding TR and OS.

Conclusions

Our prognostic prediction model using ADV scores is an integrated quantitative surrogate biomarker for posttransplant prognosis in HCC patients and can provide reliable information that assists the decision-making for LDLT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

AFP:

α-fetoprotein

DCP:

des-γ-carboxyprothrombin

TV:

Tumor volume

ADV score:

Multiplication of AFP, DCP, and TV

AD score:

Multiplication of AFP and DCP

AMC:

Asan Medical Center

HCC:

Hepatocellular carcinoma

LDLT:

Living donor liver transplantation

LT:

Liver transplantation

mRECIST:

Modified Response Evaluation Criteria In Solid Tumors

PT:

Pretransplant-treated

TN:

Treatment-naïve

UCSF:

University of California San Francisco

References

  1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med 1996;334:693–699.

    Article  CAS  Google Scholar 

  2. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–1403.

    Article  CAS  Google Scholar 

  3. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008;14:935–945.

    Article  Google Scholar 

  4. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009;49:832–838.

    Article  Google Scholar 

  5. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009;9:2362–2371.

    Article  CAS  Google Scholar 

  6. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35–43.

    Article  Google Scholar 

  7. Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Multiplication of tumor volume by two tumor markers is a post-resection prognostic predictor for solitary hepatocellular carcinoma. J Gastrointest Surg 2016;20:1807–1820.

    Article  Google Scholar 

  8. Jung DH, Hwang S, Lee YJ, Kim KH, Song GW, Ahn CS, et al. Small hepatocellular carcinoma with low tumor marker expression benefits more from anatomical resection than tumors with aggressive biology. Ann Surg 2019;269:511–519.

    Article  Google Scholar 

  9. Hwang S, Joh JW, Wang HJ, Kim DG, Kim KS, Suh KS, et al. Prognostic prediction models for resection of large hepatocellular carcinoma: A Korean multicenter study. World J Surg 2018;42:2579–2591.

    Article  Google Scholar 

  10. Ha SM, Hwang S, Park JY, Lee YJ, Kim KH, Song GW, et al. Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas. Ann Surg Treat Res 2018;95:303–311.

    Article  CAS  Google Scholar 

  11. Hwang S, Moon DB, Ahn CS, Kim KH, Ha TY, Song GW, et al. Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation. Transplant Proc 2013;45:3076–3084.

    Article  CAS  Google Scholar 

  12. Alshahrani AA, Ha SM, Hwang S, Ahn CS, Kim KH, et al. Clinical features and surveillance of very late hepatocellular carcinoma recurrence after liver transplantation. Ann Transplant 2018;23:659–665.

    Article  Google Scholar 

  13. The Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18–75.

    Article  Google Scholar 

  14. Jung DH, Tak E, Hwang S, Song GW, Ahn CS, Kim KH, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence. Liver Transpl 2018;24:932–945.

    Article  Google Scholar 

  15. Hwang S, Kim YH, Kim DK, Ahn CS, Moon DB, Kim KH, et al. Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation. World J Surg 2012;36:1592–1602.

    Article  Google Scholar 

  16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52–60.

    Article  CAS  Google Scholar 

  17. Kim HD, Shim JH, Kim GA, Shin YM, Yu E, Lee SG, et al. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. J Hepatol 2015;62:1076–1784.

    Article  Google Scholar 

  18. Galizia MS, Töre HG, Chalian H, Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol 2011;18:1555–60.

    Article  Google Scholar 

  19. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018;154:128–139.

    Article  Google Scholar 

  20. Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260–1267.

    Article  Google Scholar 

  21. Sandow TA, Arndt SE, Albar AA, DeVun DA, Kirsch DS, Gimenez JM, et al. Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort. Radiology 2018;286:1072–1083.

    Article  Google Scholar 

  22. Kang WH, Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, et al. Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma. Liver Transpl 2017;23:781–790.

    Article  Google Scholar 

  23. Botea F, Marconi M, Lutman F, Balzarini L, Roncalli M, Montorsi M, et al. Radiological estimation of size in colorectal liver metastases: is it reliable? Comparison with post-resectional measurements. Updates Surg 2010;62:21–26.

    Article  Google Scholar 

  24. Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, et al. Super-selection of a subgroup of hepatocellular carcinoma patients at minimal risk of recurrence for liver transplantation. J Gastrointest Surg 2011;15:971–981.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shin Hwang.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 54 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hwang, S., Song, GW., Ahn, CS. et al. Quantitative Prognostic Prediction Using ADV Score for Hepatocellular Carcinoma Following Living Donor Liver Transplantation. J Gastrointest Surg 25, 2503–2515 (2021). https://doi.org/10.1007/s11605-021-04939-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-021-04939-w

Keywords

Navigation